# Glaucoma Agents

## Length of Authorizations

365 Days

## Prior Authorization Criteria

Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:

-   Allergy to medications not requiring prior approval
-   Contraindications to or drug interaction with medications not requiring prior approval
-   History of unacceptable/toxic side effects to medications not requiring prior approval

## Additional Criteria
### Step Therapy

Step Therapy Approval Criteria

1.  For a product requiring step therapy, there must have been inadequate clinical response to preferred alternatives for glaucoma, including a trial of no less than **30 days** of at least **one** preferred product
2.  For a non-preferred agent for glaucoma, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than **30 days each** of at least **two** preferred or step therapy products

## Formulary

Ophthalmic Agents: Glaucoma Agents

### Preferred

| Preferred            |
| :------------------- |
| Alphagan P 0.1% ST   |
| Alphagan P 0.15% BvG |
| Azopt BvG ST         |
| Betaxolol            |
| Brimonidine 0.2%     |
| Carteolol            |
| Combigan BvG ST      |
| Dorzolamide          |
| Dorzolamide/Timolol  |
| Latanaprost          |
| Levobunolol          |
| Metipranolol         |
| Rhopressa            |
| Rocklatan            |
| Simbrinza            |
| Timolol              |
| Travatan Z BvG ST    |

### Non-Preferred

| Non-Preferred     |
| :---------------- |
| Apraclonidine     |
| Betoptic S        |
| Bimatoprost       |
| Brimonidine 0.15% |
| Brinzolamide      |
| Iopidine          |
| Istalol           |
| Lumigan           |
| Travoprost        |
| Vyzulta           |
| Xelpros           |
| Zioptan           |

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=85)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=29)